![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RGS22 |
Gene summary for RGS22 |
![]() |
Gene information | Species | Human | Gene symbol | RGS22 | Gene ID | 26166 |
Gene name | regulator of G protein signaling 22 | |
Gene Alias | CT145 | |
Cytomap | 8q22.2 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8NE09 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26166 | RGS22 | ATC13 | Human | Thyroid | ATC | 7.40e-31 | 5.11e-01 | 0.34 |
26166 | RGS22 | ATC5 | Human | Thyroid | ATC | 1.12e-33 | 5.68e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RGS22 | SNV | Missense_Mutation | c.3662N>T | p.Arg1221Ile | p.R1221I | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RGS22 | SNV | Missense_Mutation | c.1259N>C | p.Lys420Thr | p.K420T | Q8NE09 | protein_coding | tolerated(0.24) | benign(0.015) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RGS22 | SNV | Missense_Mutation | novel | c.3283N>A | p.Asp1095Asn | p.D1095N | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RGS22 | SNV | Missense_Mutation | novel | c.2072A>C | p.Lys691Thr | p.K691T | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RGS22 | SNV | Missense_Mutation | novel | c.295G>A | p.Ala99Thr | p.A99T | Q8NE09 | protein_coding | tolerated(0.56) | benign(0.006) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RGS22 | SNV | Missense_Mutation | novel | c.2229N>T | p.Lys743Asn | p.K743N | Q8NE09 | protein_coding | tolerated(0.07) | possibly_damaging(0.773) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RGS22 | SNV | Missense_Mutation | novel | c.375N>C | p.Lys125Asn | p.K125N | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
RGS22 | insertion | Frame_Shift_Ins | novel | c.2236_2237insT | p.Glu746ValfsTer11 | p.E746Vfs*11 | Q8NE09 | protein_coding | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
RGS22 | insertion | Frame_Shift_Ins | novel | c.3642_3643insTA | p.Glu1215Ter | p.E1215* | Q8NE09 | protein_coding | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RGS22 | SNV | Missense_Mutation | novel | c.2883N>C | p.Arg961Ser | p.R961S | Q8NE09 | protein_coding | deleterious(0) | possibly_damaging(0.575) | TCGA-CC-A8HT-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |